Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × aflutinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 NSCLC 8 Adenocarcinoma of Lung 4 Meningeal Carcinomatosis 3 Lung Neoplasms 3 Brain Neoplasms 3 Respiratory Tract Neoplasms 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Bronchial Neoplasms 1 Advanced Non-small Cell Lung Cancer 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1 Advanced Lung Cancer 1 Adenocarcinoma 1

Interventions

Carboplatin 20 Cisplatin 15 Pemetrexed 14 pembrolizumab 13 Paclitaxel 13 Gemcitabine 8 osimertinib 6 durvalumab 6 Docetaxel 6 Nivolumab 5 Erlotinib Hydrochloride 4 130-nm albumin-bound paclitaxel 4 brigatinib 3 Gefitinib 3 vosaroxin 2 volociximab 2 pralsetinib 2 ensartinib 2 atezolizumab 2 anlotinib 2 aflibercept 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Ipilimumab 2 Drug Therapy 2 Cyclophosphamide 2 Cetuximab 2 Albumin-Bound Paclitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡